Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis
Abstract
ObjectivesAllergic conjunctivitis (AC) affects 15%–40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents.MethodsRegistered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed.ResultsNineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate.ConclusionTopical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.
Related
- Olopatadine in Seasonal Allergic Conjunctivitis: Efficacy, Ocular Surface Safety, and Practical Considerations for Preservative-Free Multidose Therapy
- Comparative efficacy and safety of dupilumab and swallowed topical corticosteroid formulations in eosinophilic esophagitis : A systematic review and network meta-analysis of randomized controlled trials
- Comparative evaluation of the antipyretic and analgesic efficacy and safety of a fast-release paracetamol 650 mg formulation vs. conventional paracetamol formulations in adults with acute febrile or febrile-pain conditions: a multicenter randomized controlled trial
- Comparative efficacy of uniportal and multiportal robotic-assisted thoracoscopic surgery for non-small cell lung cancer: a systematic review and meta-analysis
- Comparative Efficacy and Safety of Systemic Immunomodulatory Therapies for Non‐Infectious Uveitis: A Systematic Review With Pairwise and Network Meta‐Analyses
BibTeX
@article{li2026comparative,
title = {{Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis}},
author = {Caiju Li and Yuying Gao and Lijuan Wei},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1914064},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1914064},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Comparative efficacy and safety of topical olopatadine formulations for allergic conjunctivitis: a systematic review and network meta-analysis
AU - Caiju Li
AU - Yuying Gao
AU - Lijuan Wei
PY - 2026
DA - 2026/11/02
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1914064
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1914064
AB - ObjectivesAllergic conjunctivitis (AC) affects 15%–40% of the global population. Traditional network meta-analyses often group different formulations of olopatadine into a single node, obscuring concentration-dependent variations. This network meta-analysis evaluated the relative efficacy and safety of distinct olopatadine concentrations (0.1%, 0.2%, 0.77%) against other topical anti-allergic or anti-inflammatory agents.MethodsRegistered in PROSPERO (CRD420261375330), this study systematically searched major databases up to 1 May 2026, for randomized controlled trials (RCTs) on adults with AC. Interventions evaluated olopatadine formulations (0.1% BID, 0.2% QD, 0.77% QD) as independent nodes alongside 0.05% epinastine, 0.025% ketotifen, 0.25% alcaftadine, 1.5% bepotastine, 0.2% loteprednol etabonate, or placebo. Frequentist random-effects network meta-analyses were performed.ResultsNineteen randomized controlled trials (RCTs) encompassing 2,745 patients (5,141 eyes) were analyzed. For ocular itching (18 RCTs), 0.77% olopatadine demonstrated superior efficacy among dual-acting agents (SUCRA = 80.7%), significantly outperforming epinastine and ketotifen. For conjunctival hyperemia (17 RCTs), 0.25% alcaftadine demonstrated the highest likelihood of efficacy (SUCRA = 66.5%), whereas among olopatadine formulations, only 0.2% significantly outperformed placebo (SUCRA = 47.4%). Subgroup analyses showed that 0.77% olopatadine and 0.25% alcaftadine were particularly effective against acute itching in conjunctival allergen challenge models. Safety assessments across 11 RCTs yielded wide confidence intervals due to data sparsity, precluding definitive tolerability rankings. Although trial data predominantly reported mild adverse events, external evidence highlights key long-term safety concerns, notably intraocular pressure elevation associated with extended topical corticosteroid therapy such as 0.2% loteprednol etabonate.ConclusionTopical dual-acting agents demonstrate outcome-specific efficacy variations in allergic conjunctivitis management. Olopatadine 0.77% excels in pruritus control, whereas alcaftadine 0.25% provides the highest likelihood of hyperemia resolution. Clinical management should adopt a personalized step-ladder approach: utilizing potent once-daily dual-acting agents (0.77% olopatadine or 0.25% alcaftadine) as first-line therapy for acute or seasonal exposure. Short-term topical corticosteroids (such as 0.2% loteprednol etabonate) should be strictly reserved for severe natural exposure non-responsive to dual-acting agents, with mandatory intraocular pressure monitoring, before transitioning back to dual-acting maintenance.
SN - 1663-9812
ER -